Jingtian & Gongcheng
Jingtian & Gongcheng is recommended for handling acquisitions and equity takeovers in the PRC healthcare and life sciences market, regularly assisting Chinese companies in this capacity. The firm is also well-recommended for overseeing collaborations in this space, including between research and development companies and major hospitals. The team, which is noted for its ability to ‘understand the needs of customers and provide very practical and operable legal opinions’, is jointly led by the corporate matters and licensing focussed Hanshuo Zhou and IPOs expert Yuanpeng Lang.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The life science and health care team of Jingtian & Gongcheng is excellent and strong. It has brilliant capabilities in serving listed companies, technology-based enterprises and innovative enterprises.’
‘I recommend Attorney Zhou and his team as an excellent group of lawyers in the field of healthcare.'
‘We do appreciate the service levels with JTGC. They showed us a fine definition of team work.’
‘From my experience working with them, they have the consciousness to put themselves in our shoes, which is a very positive attitude.'
‘The team's capabilities are very comprehensive, showing a high degree of investment in the project they are tasked with and a strong ability to integrate with the customer's business.'’
‘Lawyer Zhou Hanshuo has a very comprehensive and in-depth understanding of the field of life sciences. He can quickly understand the key points of the client's business and major risks, and with his many years of work experience in this industry, he can proactively put forward very valuable suggestions.’
‘They have rich experience in this field, and sufficient knowledge and understanding of laws and regulations in this field to provide customers with practical advice.’
‘Zhou Hanshuo and his team are able to understand the needs of customers and provide very practical and operable legal opinions and suggestions.’
Key clients
- Thermo Fisher Scientific
- BGI and MGI
- Qitan Tech
- Santen
- 3SBio
- LYFE Capital
- the C.Q. Pharmaceutical Group
- Shanghai RNAcure Biopharma Co., Ltd.
- CPE
- China Resources Zizhu Pharmaceutical Co. Ltd.
- Beijing Tong Ren Tang Co., Ltd. Yes
- Tong Ren Tang Technologies Co., Ltd. Yes
- Beijing Tong Ren Tang Chinese Medicine Company Limited
- CCB Private Equity Investment Management Co., Ltd.
- Pullos Jianfa (Xiamen) Equity Investment Fund Partnership (Limited Partnership)
Work highlights
- Represented China General Technology (Group) Holding Co Ltd (“Genertec”) in its acquisition of Baoshihua Medical Group from 7 institutional investors including China National Petroleum Corporation.
- Assisted Conba with transferring 49.84% equity of Jiangxi Zhen Shi Ming Pharmaceutical (“ZSM”) to a group of both domestic and foreign investors.
- Advised China Isotope & Radiation Corporation on its collaboration project with several domestic hospitals, including Peking Union Medical College Hospital.
Practice head
The lawyer(s) leading their teams.
Yuanpeng Lang, Hanshuo Zhou